New steps forward in treating Alzheimer’s disease with lecanemab: Clinical trial reveals clear efficacy in removing brain plaque
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for…
DS-CTN Data and Safety Monitoring Board (DSMB)
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch…
Kate O’NeillNovember 16, 2022
Lecanemab: New Treatment for Alzheimer’s Disease
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced…
Kate O’NeillNovember 1, 2022
NTG Publishes Advisory on Long-COVID in Adults with Intellectual Disability
In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices (NTG)…
Kate O’NeillOctober 17, 2022
Why is Down syndrome research important?
Learn more about Down syndrome research Learn more about resources for families Learn more about…
Kate O’NeillOctober 3, 2022
Potential New Therapy for Adults with Down Syndrome
September 16, 2022 Research recently published in the journal Science (Manfredi-Lozano et al., Science 377,…
Kate O’NeillSeptember 16, 2022
LIFE-DSR: up close and personal with John
In July 2022, John Cronin and his parents invited LuMind IDSC to follow their family…
Kate O’NeillSeptember 7, 2022
A Closer Look at the CMS Decision on Aduhelm and Anti-Amyloid Drugs
AN EXPLAINER FOR THE DOWN SYNDROME COMMUNITY April 15, 2022 BACKGROUND On April 7,…
CapetivateApril 19, 2022
Caregivers Evaluate Independence in Individuals with Down Syndrome
Institutions: Division of Medical Genetics and Metabolism at Massachusetts General Hospital, LuMind IDSC Foundation, the Department…
CapetivateMarch 3, 2022